Nemesis Bioscience today announced the appointment of Dr Mark McCamish as Scientific Advisor for the development of its suite of Bacterial Cybergenetics© technologies. These include Nemesis Symbiotics© for applications including the reversal of antibiotic resistance and Transmids© for their clinical, veterinary and industrial delivery.
Mark, an investor in Nemesis, is currently President and CEO of Forty Seven Inc and until recently led development of all biologics at Sandoz Biopharmaceuticals. His responsibilities included selection of the target, cloning, technical development, scale-up, pre-clinical and clinical development of biologics including interfaces with regulatory authorities worldwide. He is a senior executive with extensive therapeutic and commercial experience in global pharmaceutical and biotechnology companies including PDL Biopharma, Facet Biotech, Perlegen, Amgen and Abbott Laboratories. He is passionate about finding solutions to unmet medical needs.
Commenting on his support of Nemesis Bioscience Mark said, “Dramatic expansion of antibiotic resistance continues to be a major threat in society and the unique technology that Nemesis is pioneering to reverse antibiotic resistance in multiple approaches is truly remarkable. I look forward to seeing their progress.”
Nemesis CEO Dr Frank Massam said the company was “absolutely delighted that we have been able to attract an advisor of Mark’s calibre and that he is excited about the clinical potential of our technologies to make a real contribution to the fight against antibiotic resistance. We look forward to working closely with Mark to advance both the treatment, prevention and probiotic possibilities of our approach.”